Blood-based treatment compared with antihistamines for long-lasting hives of unknown cause
Compares a person's own blood injections with high-dose antihistamines in adults with chronic idiopathic urticaria.
Key facts
- Who runs it
- Cairo University
- Where
- Egypt1 site in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- Autologous Whole Blood Therapy in Chronic Idiopathic Urticaria Patients.
- Status
- Not yet recruiting
- Phase
- Phase 3
- People taking part
- 40 people, planned
- Started
- 30 Apr 2026
- Expected to end
- 30 Nov 2026
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Autologous whole blood therapy
- Desloratadine
- Record updated
- 20 March 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with chronic idiopathic urticaria (long-lasting hives with no known cause) that did not improve on four-fold doses of antihistamines.
- Age
- 18 years or older
- Sex
- All sexes
- Disease stage
- Chronic idiopathic urticaria. People with a positive or a negative autologous serum skin test (ASST) can join.
- Earlier treatment
- Hives must not have improved on four-fold doses of antihistamines. No systemic corticosteroid or immunosuppressive drugs in the past 6 weeks.
Main reasons for not taking part
- Other types of chronic urticaria
- Pregnancy or breastfeeding
- Weak immune system
- History of bronchial asthma
- Taking anticoagulants (blood thinners) or non-steroidal anti-inflammatory drugs
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- Chronic idiopathic urticaria patients of both sexes aging 18 years of age or older who are unresponsive to four-fold of antihistamines
Who cannot take part
- Patients on Systemic corticosteroid or immunosuppressive drugs used in the past 6 weeks
- Patients on non-steroidal anti-inflammatory drugs
- History of Bronchial Asthma
- other types of chronic urticaria
- Pregnancy
- Lactation
- Immunocompromised patients
- Patients on anticoagulants
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
To evaluate the efficacy of Autologous Whole Blood Therapy versus conventional treatment using fourfold dose of antihistamines in Autologus serum skin test (ASST) positive and negative Chronic Idiopathic Urticaria (CIU) patients and suggest its possible mechanism of action.
The 2 groups in the trial
- AWBT plus antihistaminesTreatment being tested
All patients will take desloratadine 10 mg at four-fold dose daily The AWBT test group patients will receive 8 doses of autologous whole blood therapy (AWBT) once weekly. The first dose will be 2.5ml and subsequent doses will be 5ml of venous blood, which will be drawn from any accessible vein under aseptic precautions. The blood will be re-injected immediately by deep intramuscular injection (IM) on alternate gluteal regions.
Treatment: Autologous whole blood therapy and Desloratadine
- antihistamines aloneExisting treatment, for comparison
All patients will take desloratadine 10 mg at four-fold dose daily
Treatment: Desloratadine
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Autologous Whole Blood Therapy in Autologous Serum Skin Test (ASST) Positive and Negative Chronic Idiopathic Urticaria Patients, a Clinical and Biochemical Randomized Controlled Trial.
- Plain-language title
- Blood-based treatment compared with antihistamines for long-lasting hives of unknown causeGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Record updated
- 20 March 2026